90481364 - T

Information

  • Trademark
  • 90481364
  • Serial Number
    90481364
  • Filing Date
    January 22, 2021
    4 years ago
  • Transaction Date
    July 11, 2022
    3 years ago
  • Status Date
    July 09, 2022
    3 years ago
  • Published for Opposition Date
    September 07, 2021
    3 years ago
  • Location Date
    July 09, 2022
    3 years ago
  • Status Code
    604
  • Current Location
    TTAB
    Employee Name
    MICHELI, ANGELA M
  • Attorney Docket Number
    10214-00502-
    Attorney Name
    HOANG CHI TRUONG
    Law Office Assigned Location Code
    L10
  • Owners
Mark Drawing Code
3000
Mark Identification
T
Case File Statements
  • DM0000: The mark consists of a capitalized letter "T" in stylized form.
  • GS0051: Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection
  • GS0441: Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; providing medical immunosequencing-based testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of person
  • GS0421: Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples
Case File Event Statements
  • 7/11/2022 - 3 years ago
    17 - ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION Type: MAB4
  • 7/9/2022 - 3 years ago
    16 - ABANDONMENT - AFTER INTER PARTES DECISION Type: ABN4
  • 7/9/2022 - 3 years ago
    15 - OPPOSITION TERMINATED NO. 999999 Type: OP.T
  • 7/9/2022 - 3 years ago
    14 - OPPOSITION SUSTAINED NO. 999999 Type: OP.S
  • 11/24/2021 - 3 years ago
    13 - OPPOSITION INSTITUTED NO. 999999 Type: OP.I
  • 9/15/2021 - 3 years ago
    12 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF
  • 9/7/2021 - 3 years ago
    11 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/7/2021 - 3 years ago
    10 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/18/2021 - 3 years ago
    9 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/2/2021 - 3 years ago
    8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/28/2021 - 4 years ago
    7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 7/28/2021 - 4 years ago
    6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 7/28/2021 - 4 years ago
    5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 7/28/2021 - 4 years ago
    4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 7/20/2021 - 4 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/23/2021 - 4 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 1/26/2021 - 4 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP